Fiduciary Alliance LLC Lowers Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Fiduciary Alliance LLC trimmed its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 15.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,335 shares of the company’s stock after selling 625 shares during the period. Fiduciary Alliance LLC’s holdings in TransMedics Group were worth $224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Janney Montgomery Scott LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $239,000. CENTRAL TRUST Co lifted its holdings in TransMedics Group by 162.2% in the fourth quarter. CENTRAL TRUST Co now owns 1,442 shares of the company’s stock valued at $90,000 after acquiring an additional 892 shares during the period. Jennison Associates LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $555,000. Tempus Wealth Planning LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $346,000. Finally, Guidance Capital Inc. lifted its holdings in TransMedics Group by 54.5% in the fourth quarter. Guidance Capital Inc. now owns 3,642 shares of the company’s stock valued at $222,000 after acquiring an additional 1,284 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Trading Up 3.9%

Shares of TMDX stock opened at $128.74 on Wednesday. The firm has a 50-day moving average price of $97.54 and a 200 day moving average price of $79.14. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of 136.96 and a beta of 1.91. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the company posted $0.35 EPS. The firm’s revenue for the quarter was up 48.2% on a year-over-year basis. Research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Oppenheimer lifted their price target on TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Tuesday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $126.70.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the sale, the director now owns 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,732 shares of company stock valued at $1,416,710. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.